Author

Baishan Jiang

Harvard UniversityORCID 0000-0001-6796-9500Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:host-pathogen & immune response· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

Adam Stuart KibeliD· 1 shared Anne FassliD· 1 shared Celine Pana· 1 shared Cheryl M. LewisiD· 1 shared Fu GuiiD· 1 shared Gary Andrew BradshawiD· 1 shared Jens W. KöllermanniD· 1 shared Jia LiiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adam Stuart KibelORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintNov 11, 2025

The non-kinase function of CDK6 is a key driver of acquired resistance to CDK4/6 inhibitors in Estrogen Receptor-positive breast cancer

S. M. Nashir Udden, Baishan Jiang, Kamal Pandey…·Prasanna G. Alluri

This study shows that CDK6's non-kinase function drives resistance to CDK4/6 inhibitors in ER+ breast cancer, challenging the assumption that kinase inhibition is the main therapeutic target.

DOI 10.1101/2025.11.11.687883

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyScience AdvancesPeer-reviewedApr 23, 2025

Acute BRCAness Induction and AR Signaling Blockage through CDK12/7/9 Degradation Enhances PARP Inhibitor Sensitivity in Prostate Cancer

Fu Gui, Baishan Jiang, Jie Jiang…·Jia Li

This paper introduces BSJ-5-63, a PROTAC that degrades CDK12, CDK7, and CDK9, inducing BRCAness and blocking AR signaling to enhance PARP inhibitor sensitivity in prostate cancer.

21 citationstop 2%

humanexperimental assay

𝕏 PostBluesky